# NCT03652064 (NCT03652064)

> A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03652064
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Janssen Research & Development, LLC
- Conditions: Multiple Myeloma
- Interventions: Daratumumab; Bortezomib; Lenalidomide; Dexamethasone
- Enrollment: 395
- Primary outcome: Primary Analysis: Overall Minimal Residual Disease (MRD) Negative Rate
- Primary outcome: Final Progression-Free Survival (PFS) Analysis : Overall Minimal Residual Disease (MRD) Negative Rate

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 87
- YouTube: 85
- Podcasts: 43
- X videos: 4
- Bluesky threads: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct03652064

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03652064", "email": "<work email>"}; the inbox owner confirms by the emailed link.